Inari Medical price target raised to $67 from $66 at Baird

Baird raised the firm’s price target on Inari Medical (NARI) to $67 from $66 and keeps an Outperform rating on the shares. The firm estimates the company delivered mid-to-high-teens US VTE growth, which suggests the company is holding share better than some expected and Baird continues to argue for more sustainable multiple expansion as “bearish” debates seem to hold less ground.